The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal ...

In the fight against COVID-19, two FDA-approved mRNA vaccines were developed by Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), which produce the SARS-CoV-2 spike protein to activate potent B and ...

The vast majority of people in a study with long COVID had experienced multiple SARS-CoV-2 infections over the course of a ...

January 2025 marks five years since the beginning of the COVID-19 pandemic that resulted in 1,216,305 American deaths and ...

Newly developed vaccine could protect against emerging SARS-CoV-2 variants and related coronaviruses that may jump from ...

“Although individual vaccines have been developed and approved for use in humans against SARS-CoV-2 and influenza viruses, ...

Viruses are masters at disguise. When they are pushed too far by our immune system, they send new virus variants into play ...

Vaccination prior to COVID-19 infection does not significantly affect neurological symptoms in patients with postacute sequelae of SARS-CoV-2 infection.

The following is a summary of “Evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality ...

The Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan has been awarded a $24 million grant ...

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.